nodes	percent_of_prediction	percent_of_DWPC	metapath
Anagrelide—CYP1A2—Carbamazepine—epilepsy syndrome	0.0902	0.203	CbGbCtD
Anagrelide—CYP1A2—Primidone—epilepsy syndrome	0.0842	0.19	CbGbCtD
Anagrelide—CYP1A2—Propofol—epilepsy syndrome	0.0754	0.17	CbGbCtD
Anagrelide—CYP1A2—Phenobarbital—epilepsy syndrome	0.0721	0.162	CbGbCtD
Anagrelide—CYP1A2—Diazepam—epilepsy syndrome	0.0683	0.154	CbGbCtD
Anagrelide—CYP1A2—Valproic Acid—epilepsy syndrome	0.0539	0.121	CbGbCtD
Anagrelide—PDE3A—GPCR downstream signaling—GABBR1—epilepsy syndrome	0.000133	0.00229	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CHRM3—epilepsy syndrome	0.000132	0.00227	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—GRM5—epilepsy syndrome	0.000132	0.00227	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCR10—epilepsy syndrome	0.00013	0.00224	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—HRH3—epilepsy syndrome	0.000127	0.0022	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CX3CR1—epilepsy syndrome	0.000126	0.00218	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—OPRM1—epilepsy syndrome	0.000125	0.00216	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—CDC42—epilepsy syndrome	0.000125	0.00215	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CX3CL1—epilepsy syndrome	0.000124	0.00214	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—BDKRB1—epilepsy syndrome	0.000124	0.00214	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CHRM2—epilepsy syndrome	0.000124	0.00214	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—GABBR1—epilepsy syndrome	0.000121	0.00208	CbGpPWpGaD
Anagrelide—Rash—Vigabatrin—epilepsy syndrome	0.00012	0.000242	CcSEcCtD
Anagrelide—Dizziness—Felbamate—epilepsy syndrome	0.00012	0.000242	CcSEcCtD
Anagrelide—Dermatitis—Vigabatrin—epilepsy syndrome	0.00012	0.000242	CcSEcCtD
Anagrelide—Urethral disorder—Topiramate—epilepsy syndrome	0.00012	0.000242	CcSEcCtD
Anagrelide—Pruritus—Oxcarbazepine—epilepsy syndrome	0.00012	0.000241	CcSEcCtD
Anagrelide—Convulsion—Pregabalin—epilepsy syndrome	0.00012	0.000241	CcSEcCtD
Anagrelide—Vision blurred—Gabapentin—epilepsy syndrome	0.00012	0.00024	CcSEcCtD
Anagrelide—Headache—Vigabatrin—epilepsy syndrome	0.00012	0.00024	CcSEcCtD
Anagrelide—Hypertension—Pregabalin—epilepsy syndrome	0.00012	0.00024	CcSEcCtD
Anagrelide—Vomiting—Diazepam—epilepsy syndrome	0.00012	0.00024	CcSEcCtD
Anagrelide—Anorexia—Valproic Acid—epilepsy syndrome	0.000119	0.000239	CcSEcCtD
Anagrelide—Rash—Diazepam—epilepsy syndrome	0.000119	0.000238	CcSEcCtD
Anagrelide—Dermatitis—Diazepam—epilepsy syndrome	0.000118	0.000238	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—CCR3—epilepsy syndrome	0.000118	0.00204	CbGpPWpGaD
Anagrelide—Visual impairment—Topiramate—epilepsy syndrome	0.000118	0.000237	CcSEcCtD
Anagrelide—Myalgia—Pregabalin—epilepsy syndrome	0.000118	0.000237	CcSEcCtD
Anagrelide—Arthralgia—Pregabalin—epilepsy syndrome	0.000118	0.000237	CcSEcCtD
Anagrelide—Chest pain—Pregabalin—epilepsy syndrome	0.000118	0.000237	CcSEcCtD
Anagrelide—Ill-defined disorder—Gabapentin—epilepsy syndrome	0.000118	0.000237	CcSEcCtD
Anagrelide—Dizziness—Zonisamide—epilepsy syndrome	0.000118	0.000237	CcSEcCtD
Anagrelide—Headache—Diazepam—epilepsy syndrome	0.000118	0.000237	CcSEcCtD
Anagrelide—Diarrhoea—Clonazepam—epilepsy syndrome	0.000117	0.000236	CcSEcCtD
Anagrelide—Anaemia—Gabapentin—epilepsy syndrome	0.000117	0.000236	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	0.000117	0.000235	CcSEcCtD
Anagrelide—Hypotension—Valproic Acid—epilepsy syndrome	0.000117	0.000235	CcSEcCtD
Anagrelide—Asthenia—Carbamazepine—epilepsy syndrome	0.000117	0.000235	CcSEcCtD
Anagrelide—Diarrhoea—Phenytoin—epilepsy syndrome	0.000117	0.000234	CcSEcCtD
Anagrelide—Discomfort—Pregabalin—epilepsy syndrome	0.000116	0.000234	CcSEcCtD
Anagrelide—Nausea—Fosphenytoin—epilepsy syndrome	0.000116	0.000234	CcSEcCtD
Anagrelide—Diarrhoea—Oxcarbazepine—epilepsy syndrome	0.000116	0.000233	CcSEcCtD
Anagrelide—Vomiting—Felbamate—epilepsy syndrome	0.000116	0.000232	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—HRH3—epilepsy syndrome	0.000116	0.00199	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—NPY—epilepsy syndrome	0.000115	0.00199	CbGpPWpGaD
Anagrelide—Dry mouth—Pregabalin—epilepsy syndrome	0.000115	0.000232	CcSEcCtD
Anagrelide—Pruritus—Carbamazepine—epilepsy syndrome	0.000115	0.000231	CcSEcCtD
Anagrelide—Rash—Felbamate—epilepsy syndrome	0.000115	0.00023	CcSEcCtD
Anagrelide—Eye disorder—Topiramate—epilepsy syndrome	0.000115	0.00023	CcSEcCtD
Anagrelide—Dermatitis—Felbamate—epilepsy syndrome	0.000115	0.00023	CcSEcCtD
Anagrelide—Malaise—Gabapentin—epilepsy syndrome	0.000114	0.00023	CcSEcCtD
Anagrelide—Tinnitus—Topiramate—epilepsy syndrome	0.000114	0.00023	CcSEcCtD
Anagrelide—Headache—Felbamate—epilepsy syndrome	0.000114	0.000229	CcSEcCtD
Anagrelide—Confusional state—Pregabalin—epilepsy syndrome	0.000114	0.000229	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	0.000114	0.000229	CcSEcCtD
Anagrelide—Cardiac disorder—Topiramate—epilepsy syndrome	0.000114	0.000229	CcSEcCtD
Anagrelide—Syncope—Gabapentin—epilepsy syndrome	0.000114	0.000229	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—OPRM1—epilepsy syndrome	0.000114	0.00196	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GRM2—epilepsy syndrome	0.000114	0.00196	CbGpPWpGaD
Anagrelide—Dizziness—Clonazepam—epilepsy syndrome	0.000114	0.000228	CcSEcCtD
Anagrelide—Nausea—Vigabatrin—epilepsy syndrome	0.000113	0.000228	CcSEcCtD
Anagrelide—Vomiting—Zonisamide—epilepsy syndrome	0.000113	0.000227	CcSEcCtD
Anagrelide—Insomnia—Valproic Acid—epilepsy syndrome	0.000113	0.000227	CcSEcCtD
Anagrelide—Oedema—Pregabalin—epilepsy syndrome	0.000113	0.000227	CcSEcCtD
Anagrelide—Asthenia—Lamotrigine—epilepsy syndrome	0.000113	0.000227	CcSEcCtD
Anagrelide—Dizziness—Phenytoin—epilepsy syndrome	0.000113	0.000226	CcSEcCtD
Anagrelide—Rash—Zonisamide—epilepsy syndrome	0.000112	0.000226	CcSEcCtD
Anagrelide—Infection—Pregabalin—epilepsy syndrome	0.000112	0.000225	CcSEcCtD
Anagrelide—Paraesthesia—Valproic Acid—epilepsy syndrome	0.000112	0.000225	CcSEcCtD
Anagrelide—Palpitations—Gabapentin—epilepsy syndrome	0.000112	0.000225	CcSEcCtD
Anagrelide—Dermatitis—Zonisamide—epilepsy syndrome	0.000112	0.000225	CcSEcCtD
Anagrelide—Dizziness—Oxcarbazepine—epilepsy syndrome	0.000112	0.000225	CcSEcCtD
Anagrelide—Nausea—Diazepam—epilepsy syndrome	0.000112	0.000224	CcSEcCtD
Anagrelide—Loss of consciousness—Gabapentin—epilepsy syndrome	0.000112	0.000224	CcSEcCtD
Anagrelide—Headache—Zonisamide—epilepsy syndrome	0.000112	0.000224	CcSEcCtD
Anagrelide—Dyspnoea—Valproic Acid—epilepsy syndrome	0.000111	0.000224	CcSEcCtD
Anagrelide—Diarrhoea—Carbamazepine—epilepsy syndrome	0.000111	0.000224	CcSEcCtD
Anagrelide—Pruritus—Lamotrigine—epilepsy syndrome	0.000111	0.000224	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—CXCL2—epilepsy syndrome	0.000111	0.00192	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—CRH—epilepsy syndrome	0.000111	0.00192	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—OXT—epilepsy syndrome	0.000111	0.00192	CbGpPWpGaD
Anagrelide—Shock—Pregabalin—epilepsy syndrome	0.000111	0.000223	CcSEcCtD
Anagrelide—Somnolence—Valproic Acid—epilepsy syndrome	0.000111	0.000223	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—FYN—epilepsy syndrome	0.000111	0.00191	CbGpPWpGaD
Anagrelide—Nervous system disorder—Pregabalin—epilepsy syndrome	0.000111	0.000223	CcSEcCtD
Anagrelide—Cough—Gabapentin—epilepsy syndrome	0.000111	0.000223	CcSEcCtD
Anagrelide—Thrombocytopenia—Pregabalin—epilepsy syndrome	0.000111	0.000222	CcSEcCtD
Anagrelide—Mediastinal disorder—Topiramate—epilepsy syndrome	0.000111	0.000222	CcSEcCtD
Anagrelide—Tachycardia—Pregabalin—epilepsy syndrome	0.00011	0.000222	CcSEcCtD
Anagrelide—Chills—Topiramate—epilepsy syndrome	0.00011	0.000221	CcSEcCtD
Anagrelide—Dyspepsia—Valproic Acid—epilepsy syndrome	0.00011	0.000221	CcSEcCtD
Anagrelide—Convulsion—Gabapentin—epilepsy syndrome	0.00011	0.000221	CcSEcCtD
Anagrelide—Skin disorder—Pregabalin—epilepsy syndrome	0.00011	0.00022	CcSEcCtD
Anagrelide—Hypertension—Gabapentin—epilepsy syndrome	0.00011	0.00022	CcSEcCtD
Anagrelide—Hyperhidrosis—Pregabalin—epilepsy syndrome	0.000109	0.000219	CcSEcCtD
Anagrelide—Vomiting—Clonazepam—epilepsy syndrome	0.000109	0.000219	CcSEcCtD
Anagrelide—Decreased appetite—Valproic Acid—epilepsy syndrome	0.000109	0.000218	CcSEcCtD
Anagrelide—Alopecia—Topiramate—epilepsy syndrome	0.000108	0.000218	CcSEcCtD
Anagrelide—Vomiting—Phenytoin—epilepsy syndrome	0.000108	0.000218	CcSEcCtD
Anagrelide—Rash—Clonazepam—epilepsy syndrome	0.000108	0.000217	CcSEcCtD
Anagrelide—Dermatitis—Clonazepam—epilepsy syndrome	0.000108	0.000217	CcSEcCtD
Anagrelide—Arthralgia—Gabapentin—epilepsy syndrome	0.000108	0.000217	CcSEcCtD
Anagrelide—Myalgia—Gabapentin—epilepsy syndrome	0.000108	0.000217	CcSEcCtD
Anagrelide—Chest pain—Gabapentin—epilepsy syndrome	0.000108	0.000217	CcSEcCtD
Anagrelide—Nausea—Felbamate—epilepsy syndrome	0.000108	0.000217	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	0.000108	0.000217	CcSEcCtD
Anagrelide—Vomiting—Oxcarbazepine—epilepsy syndrome	0.000108	0.000217	CcSEcCtD
Anagrelide—Fatigue—Valproic Acid—epilepsy syndrome	0.000108	0.000216	CcSEcCtD
Anagrelide—Anorexia—Pregabalin—epilepsy syndrome	0.000108	0.000216	CcSEcCtD
Anagrelide—Dizziness—Carbamazepine—epilepsy syndrome	0.000108	0.000216	CcSEcCtD
Anagrelide—Diarrhoea—Lamotrigine—epilepsy syndrome	0.000108	0.000216	CcSEcCtD
Anagrelide—Headache—Clonazepam—epilepsy syndrome	0.000108	0.000216	CcSEcCtD
Anagrelide—Rash—Phenytoin—epilepsy syndrome	0.000108	0.000216	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—CCR3—epilepsy syndrome	0.000107	0.00185	CbGpPWpGaD
Anagrelide—Dermatitis—Phenytoin—epilepsy syndrome	0.000107	0.000216	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	0.000107	0.000216	CcSEcCtD
Anagrelide—Rash—Oxcarbazepine—epilepsy syndrome	0.000107	0.000215	CcSEcCtD
Anagrelide—Constipation—Valproic Acid—epilepsy syndrome	0.000107	0.000215	CcSEcCtD
Anagrelide—Pain—Valproic Acid—epilepsy syndrome	0.000107	0.000215	CcSEcCtD
Anagrelide—Dermatitis—Oxcarbazepine—epilepsy syndrome	0.000107	0.000215	CcSEcCtD
Anagrelide—Headache—Phenytoin—epilepsy syndrome	0.000107	0.000215	CcSEcCtD
Anagrelide—Malnutrition—Topiramate—epilepsy syndrome	0.000107	0.000215	CcSEcCtD
Anagrelide—Discomfort—Gabapentin—epilepsy syndrome	0.000107	0.000214	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—YWHAZ—epilepsy syndrome	0.000107	0.00184	CbGpPWpGaD
Anagrelide—Headache—Oxcarbazepine—epilepsy syndrome	0.000106	0.000213	CcSEcCtD
Anagrelide—Nausea—Zonisamide—epilepsy syndrome	0.000106	0.000212	CcSEcCtD
Anagrelide—Dry mouth—Gabapentin—epilepsy syndrome	0.000106	0.000212	CcSEcCtD
Anagrelide—Hypotension—Pregabalin—epilepsy syndrome	0.000106	0.000212	CcSEcCtD
Anagrelide—Flatulence—Topiramate—epilepsy syndrome	0.000105	0.000211	CcSEcCtD
Anagrelide—Tension—Topiramate—epilepsy syndrome	0.000105	0.000211	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—NPY—epilepsy syndrome	0.000105	0.00181	CbGpPWpGaD
Anagrelide—Confusional state—Gabapentin—epilepsy syndrome	0.000104	0.00021	CcSEcCtD
Anagrelide—Dizziness—Lamotrigine—epilepsy syndrome	0.000104	0.000209	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CERS1—epilepsy syndrome	0.000104	0.00179	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—FAR1—epilepsy syndrome	0.000104	0.00179	CbGpPWpGaD
Anagrelide—Nervousness—Topiramate—epilepsy syndrome	0.000104	0.000208	CcSEcCtD
Anagrelide—Oedema—Gabapentin—epilepsy syndrome	0.000104	0.000208	CcSEcCtD
Anagrelide—Vomiting—Carbamazepine—epilepsy syndrome	0.000103	0.000208	CcSEcCtD
Anagrelide—Back pain—Topiramate—epilepsy syndrome	0.000103	0.000208	CcSEcCtD
Anagrelide—Feeling abnormal—Valproic Acid—epilepsy syndrome	0.000103	0.000207	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	0.000103	0.000207	CcSEcCtD
Anagrelide—Infection—Gabapentin—epilepsy syndrome	0.000103	0.000207	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—SSTR3—epilepsy syndrome	0.000103	0.00177	CbGpPWpGaD
Anagrelide—Muscle spasms—Topiramate—epilepsy syndrome	0.000103	0.000206	CcSEcCtD
Anagrelide—Rash—Carbamazepine—epilepsy syndrome	0.000103	0.000206	CcSEcCtD
Anagrelide—Dermatitis—Carbamazepine—epilepsy syndrome	0.000103	0.000206	CcSEcCtD
Anagrelide—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	0.000102	0.000205	CcSEcCtD
Anagrelide—Insomnia—Pregabalin—epilepsy syndrome	0.000102	0.000205	CcSEcCtD
Anagrelide—Nausea—Clonazepam—epilepsy syndrome	0.000102	0.000205	CcSEcCtD
Anagrelide—Headache—Carbamazepine—epilepsy syndrome	0.000102	0.000205	CcSEcCtD
Anagrelide—Shock—Gabapentin—epilepsy syndrome	0.000102	0.000205	CcSEcCtD
Anagrelide—Nervous system disorder—Gabapentin—epilepsy syndrome	0.000102	0.000204	CcSEcCtD
Anagrelide—Paraesthesia—Pregabalin—epilepsy syndrome	0.000101	0.000204	CcSEcCtD
Anagrelide—Thrombocytopenia—Gabapentin—epilepsy syndrome	0.000101	0.000204	CcSEcCtD
Anagrelide—Nausea—Phenytoin—epilepsy syndrome	0.000101	0.000203	CcSEcCtD
Anagrelide—Tachycardia—Gabapentin—epilepsy syndrome	0.000101	0.000203	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—CRH—epilepsy syndrome	0.000101	0.00174	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CCL3—epilepsy syndrome	0.000101	0.00174	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CXCL2—epilepsy syndrome	0.000101	0.00174	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—OXT—epilepsy syndrome	0.000101	0.00174	CbGpPWpGaD
Anagrelide—Dyspnoea—Pregabalin—epilepsy syndrome	0.000101	0.000202	CcSEcCtD
Anagrelide—Nausea—Oxcarbazepine—epilepsy syndrome	0.000101	0.000202	CcSEcCtD
Anagrelide—Vision blurred—Topiramate—epilepsy syndrome	0.000101	0.000202	CcSEcCtD
Anagrelide—Skin disorder—Gabapentin—epilepsy syndrome	0.000101	0.000202	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—CCR2—epilepsy syndrome	0.000101	0.00174	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—SST—epilepsy syndrome	0.000101	0.00174	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ST3GAL3—epilepsy syndrome	0.000101	0.00173	CbGpPWpGaD
Anagrelide—Somnolence—Pregabalin—epilepsy syndrome	0.0001	0.000202	CcSEcCtD
Anagrelide—Hyperhidrosis—Gabapentin—epilepsy syndrome	0.0001	0.000201	CcSEcCtD
Anagrelide—Vomiting—Lamotrigine—epilepsy syndrome	0.0001	0.000201	CcSEcCtD
Anagrelide—Urticaria—Valproic Acid—epilepsy syndrome	9.93e-05	0.000199	CcSEcCtD
Anagrelide—Rash—Lamotrigine—epilepsy syndrome	9.92e-05	0.000199	CcSEcCtD
Anagrelide—Ill-defined disorder—Topiramate—epilepsy syndrome	9.91e-05	0.000199	CcSEcCtD
Anagrelide—Dermatitis—Lamotrigine—epilepsy syndrome	9.91e-05	0.000199	CcSEcCtD
Anagrelide—Body temperature increased—Valproic Acid—epilepsy syndrome	9.88e-05	0.000198	CcSEcCtD
Anagrelide—Abdominal pain—Valproic Acid—epilepsy syndrome	9.88e-05	0.000198	CcSEcCtD
Anagrelide—Anorexia—Gabapentin—epilepsy syndrome	9.88e-05	0.000198	CcSEcCtD
Anagrelide—Anaemia—Topiramate—epilepsy syndrome	9.87e-05	0.000198	CcSEcCtD
Anagrelide—Headache—Lamotrigine—epilepsy syndrome	9.85e-05	0.000198	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—ARHGEF9—epilepsy syndrome	9.85e-05	0.0017	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCR8—epilepsy syndrome	9.85e-05	0.0017	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCR9—epilepsy syndrome	9.85e-05	0.0017	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NPY2R—epilepsy syndrome	9.85e-05	0.0017	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SSTR1—epilepsy syndrome	9.85e-05	0.0017	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—ADRA2A—epilepsy syndrome	9.85e-05	0.0017	CbGpPWpGaD
Anagrelide—Decreased appetite—Pregabalin—epilepsy syndrome	9.82e-05	0.000197	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	9.76e-05	0.000196	CcSEcCtD
Anagrelide—Fatigue—Pregabalin—epilepsy syndrome	9.74e-05	0.000196	CcSEcCtD
Anagrelide—Hypotension—Gabapentin—epilepsy syndrome	9.68e-05	0.000194	CcSEcCtD
Anagrelide—Nausea—Carbamazepine—epilepsy syndrome	9.67e-05	0.000194	CcSEcCtD
Anagrelide—Constipation—Pregabalin—epilepsy syndrome	9.66e-05	0.000194	CcSEcCtD
Anagrelide—Pain—Pregabalin—epilepsy syndrome	9.66e-05	0.000194	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—GRM4—epilepsy syndrome	9.66e-05	0.00167	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GRM3—epilepsy syndrome	9.66e-05	0.00167	CbGpPWpGaD
Anagrelide—Malaise—Topiramate—epilepsy syndrome	9.63e-05	0.000193	CcSEcCtD
Anagrelide—Syncope—Topiramate—epilepsy syndrome	9.58e-05	0.000192	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—DUSP4—epilepsy syndrome	9.48e-05	0.00164	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SSTR2—epilepsy syndrome	9.48e-05	0.00164	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PLAU—epilepsy syndrome	9.47e-05	0.00163	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—BDKRB2—epilepsy syndrome	9.46e-05	0.00163	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—CXCL12—epilepsy syndrome	9.46e-05	0.00163	CbGpPWpGaD
Anagrelide—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	9.44e-05	0.00019	CcSEcCtD
Anagrelide—Palpitations—Topiramate—epilepsy syndrome	9.44e-05	0.00019	CcSEcCtD
Anagrelide—Loss of consciousness—Topiramate—epilepsy syndrome	9.39e-05	0.000189	CcSEcCtD
Anagrelide—Insomnia—Gabapentin—epilepsy syndrome	9.37e-05	0.000188	CcSEcCtD
Anagrelide—Nausea—Lamotrigine—epilepsy syndrome	9.34e-05	0.000188	CcSEcCtD
Anagrelide—Cough—Topiramate—epilepsy syndrome	9.32e-05	0.000187	CcSEcCtD
Anagrelide—Feeling abnormal—Pregabalin—epilepsy syndrome	9.31e-05	0.000187	CcSEcCtD
Anagrelide—Paraesthesia—Gabapentin—epilepsy syndrome	9.3e-05	0.000187	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—CNR1—epilepsy syndrome	9.29e-05	0.0016	CbGpPWpGaD
Anagrelide—Convulsion—Topiramate—epilepsy syndrome	9.25e-05	0.000186	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—PLCB1—epilepsy syndrome	9.25e-05	0.0016	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—RELA—epilepsy syndrome	9.25e-05	0.00159	CbGpPWpGaD
Anagrelide—Gastrointestinal pain—Pregabalin—epilepsy syndrome	9.24e-05	0.000186	CcSEcCtD
Anagrelide—Dyspnoea—Gabapentin—epilepsy syndrome	9.24e-05	0.000186	CcSEcCtD
Anagrelide—Hypertension—Topiramate—epilepsy syndrome	9.22e-05	0.000185	CcSEcCtD
Anagrelide—Somnolence—Gabapentin—epilepsy syndrome	9.21e-05	0.000185	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—GRM8—epilepsy syndrome	9.16e-05	0.00158	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PGF—epilepsy syndrome	9.16e-05	0.00158	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CCR2—epilepsy syndrome	9.14e-05	0.00158	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—SST—epilepsy syndrome	9.14e-05	0.00158	CbGpPWpGaD
Anagrelide—Dyspepsia—Gabapentin—epilepsy syndrome	9.12e-05	0.000183	CcSEcCtD
Anagrelide—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—epilepsy syndrome	9.11e-05	0.00157	CbGpPWpGaD
Anagrelide—Myalgia—Topiramate—epilepsy syndrome	9.09e-05	0.000183	CcSEcCtD
Anagrelide—Arthralgia—Topiramate—epilepsy syndrome	9.09e-05	0.000183	CcSEcCtD
Anagrelide—Chest pain—Topiramate—epilepsy syndrome	9.09e-05	0.000183	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—HTR7—epilepsy syndrome	9.06e-05	0.00156	CbGpPWpGaD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	9.03e-05	0.000181	CcSEcCtD
Anagrelide—Decreased appetite—Gabapentin—epilepsy syndrome	9.01e-05	0.000181	CcSEcCtD
Anagrelide—Discomfort—Topiramate—epilepsy syndrome	8.98e-05	0.00018	CcSEcCtD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—epilepsy syndrome	8.98e-05	0.00155	CbGpPWpGaD
Anagrelide—Urticaria—Pregabalin—epilepsy syndrome	8.98e-05	0.00018	CcSEcCtD
Anagrelide—Asthenia—Valproic Acid—epilepsy syndrome	8.97e-05	0.00018	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	8.95e-05	0.00018	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—ADRA2A—epilepsy syndrome	8.94e-05	0.00154	CbGpPWpGaD
Anagrelide—Fatigue—Gabapentin—epilepsy syndrome	8.93e-05	0.000179	CcSEcCtD
Anagrelide—Abdominal pain—Pregabalin—epilepsy syndrome	8.93e-05	0.000179	CcSEcCtD
Anagrelide—Body temperature increased—Pregabalin—epilepsy syndrome	8.93e-05	0.000179	CcSEcCtD
Anagrelide—CYP1A2—Biological oxidations—CYP2C19—epilepsy syndrome	8.92e-05	0.00154	CbGpPWpGaD
Anagrelide—Dry mouth—Topiramate—epilepsy syndrome	8.89e-05	0.000179	CcSEcCtD
Anagrelide—CYP1A2—Biological oxidations—CYP11A1—epilepsy syndrome	8.87e-05	0.00153	CbGpPWpGaD
Anagrelide—Pain—Gabapentin—epilepsy syndrome	8.86e-05	0.000178	CcSEcCtD
Anagrelide—Constipation—Gabapentin—epilepsy syndrome	8.86e-05	0.000178	CcSEcCtD
Anagrelide—Pruritus—Valproic Acid—epilepsy syndrome	8.84e-05	0.000178	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—PRKCB—epilepsy syndrome	8.8e-05	0.00152	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—CYP2C19—epilepsy syndrome	8.8e-05	0.00152	CbGpPWpGaD
Anagrelide—Confusional state—Topiramate—epilepsy syndrome	8.79e-05	0.000177	CcSEcCtD
Anagrelide—CYP1A2—Metapathway biotransformation—CYP11A1—epilepsy syndrome	8.75e-05	0.00151	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—OPRD1—epilepsy syndrome	8.74e-05	0.00151	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GNAO1—epilepsy syndrome	8.74e-05	0.00151	CbGpPWpGaD
Anagrelide—Oedema—Topiramate—epilepsy syndrome	8.72e-05	0.000175	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—NOS2—epilepsy syndrome	8.7e-05	0.0015	CbGpPWpGaD
Anagrelide—Infection—Topiramate—epilepsy syndrome	8.66e-05	0.000174	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—AKT3—epilepsy syndrome	8.63e-05	0.00149	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CXCL12—epilepsy syndrome	8.59e-05	0.00148	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—BDKRB2—epilepsy syndrome	8.59e-05	0.00148	CbGpPWpGaD
Anagrelide—Shock—Topiramate—epilepsy syndrome	8.58e-05	0.000172	CcSEcCtD
Anagrelide—Diarrhoea—Valproic Acid—epilepsy syndrome	8.55e-05	0.000172	CcSEcCtD
Anagrelide—Nervous system disorder—Topiramate—epilepsy syndrome	8.55e-05	0.000172	CcSEcCtD
Anagrelide—Feeling abnormal—Gabapentin—epilepsy syndrome	8.54e-05	0.000171	CcSEcCtD
Anagrelide—Thrombocytopenia—Topiramate—epilepsy syndrome	8.54e-05	0.000171	CcSEcCtD
Anagrelide—Tachycardia—Topiramate—epilepsy syndrome	8.51e-05	0.000171	CcSEcCtD
Anagrelide—Gastrointestinal pain—Gabapentin—epilepsy syndrome	8.47e-05	0.00017	CcSEcCtD
Anagrelide—Skin disorder—Topiramate—epilepsy syndrome	8.47e-05	0.00017	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—CNR1—epilepsy syndrome	8.43e-05	0.00145	CbGpPWpGaD
Anagrelide—Hyperhidrosis—Topiramate—epilepsy syndrome	8.43e-05	0.000169	CcSEcCtD
Anagrelide—CYP1A2—Arachidonic acid metabolism—PTGS2—epilepsy syndrome	8.4e-05	0.00145	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PLCB1—epilepsy syndrome	8.4e-05	0.00145	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CHRM1—epilepsy syndrome	8.38e-05	0.00144	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCR7—epilepsy syndrome	8.38e-05	0.00144	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PDYN—epilepsy syndrome	8.38e-05	0.00144	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GRM1—epilepsy syndrome	8.38e-05	0.00144	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—epilepsy syndrome	8.36e-05	0.00144	CbGpPWpGaD
Anagrelide—Anorexia—Topiramate—epilepsy syndrome	8.31e-05	0.000167	CcSEcCtD
Anagrelide—Dizziness—Valproic Acid—epilepsy syndrome	8.27e-05	0.000166	CcSEcCtD
Anagrelide—Urticaria—Gabapentin—epilepsy syndrome	8.23e-05	0.000165	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—HTR7—epilepsy syndrome	8.23e-05	0.00142	CbGpPWpGaD
Anagrelide—Abdominal pain—Gabapentin—epilepsy syndrome	8.19e-05	0.000165	CcSEcCtD
Anagrelide—Body temperature increased—Gabapentin—epilepsy syndrome	8.19e-05	0.000165	CcSEcCtD
Anagrelide—Hypotension—Topiramate—epilepsy syndrome	8.15e-05	0.000164	CcSEcCtD
Anagrelide—Asthenia—Pregabalin—epilepsy syndrome	8.11e-05	0.000163	CcSEcCtD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—epilepsy syndrome	8.1e-05	0.0014	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—CYP2D6—epilepsy syndrome	8e-05	0.00138	CbGpPWpGaD
Anagrelide—Pruritus—Pregabalin—epilepsy syndrome	7.99e-05	0.000161	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—HBEGF—epilepsy syndrome	7.99e-05	0.00138	CbGpPWpGaD
Anagrelide—Vomiting—Valproic Acid—epilepsy syndrome	7.95e-05	0.00016	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	7.94e-05	0.00016	CcSEcCtD
Anagrelide—CYP1A2—Metapathway biotransformation—CYP2D6—epilepsy syndrome	7.89e-05	0.00136	CbGpPWpGaD
Anagrelide—Insomnia—Topiramate—epilepsy syndrome	7.88e-05	0.000158	CcSEcCtD
Anagrelide—Rash—Valproic Acid—epilepsy syndrome	7.88e-05	0.000158	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—CDC42—epilepsy syndrome	7.88e-05	0.00136	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GFAP—epilepsy syndrome	7.88e-05	0.00136	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GAL—epilepsy syndrome	7.88e-05	0.00136	CbGpPWpGaD
Anagrelide—Dermatitis—Valproic Acid—epilepsy syndrome	7.87e-05	0.000158	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—SLCO1A2—epilepsy syndrome	7.87e-05	0.00136	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—AKT3—epilepsy syndrome	7.84e-05	0.00135	CbGpPWpGaD
Anagrelide—Headache—Valproic Acid—epilepsy syndrome	7.83e-05	0.000157	CcSEcCtD
Anagrelide—Paraesthesia—Topiramate—epilepsy syndrome	7.83e-05	0.000157	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—GRM5—epilepsy syndrome	7.79e-05	0.00134	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CHRM3—epilepsy syndrome	7.79e-05	0.00134	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CASP2—epilepsy syndrome	7.79e-05	0.00134	CbGpPWpGaD
Anagrelide—Dyspnoea—Topiramate—epilepsy syndrome	7.77e-05	0.000156	CcSEcCtD
Anagrelide—Somnolence—Topiramate—epilepsy syndrome	7.75e-05	0.000156	CcSEcCtD
Anagrelide—Diarrhoea—Pregabalin—epilepsy syndrome	7.73e-05	0.000155	CcSEcCtD
Anagrelide—Dyspepsia—Topiramate—epilepsy syndrome	7.67e-05	0.000154	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—AVP—epilepsy syndrome	7.63e-05	0.00132	CbGpPWpGaD
Anagrelide—Decreased appetite—Topiramate—epilepsy syndrome	7.58e-05	0.000152	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Topiramate—epilepsy syndrome	7.53e-05	0.000151	CcSEcCtD
Anagrelide—Fatigue—Topiramate—epilepsy syndrome	7.52e-05	0.000151	CcSEcCtD
Anagrelide—Dizziness—Pregabalin—epilepsy syndrome	7.47e-05	0.00015	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—CX3CR1—epilepsy syndrome	7.47e-05	0.00129	CbGpPWpGaD
Anagrelide—Constipation—Topiramate—epilepsy syndrome	7.45e-05	0.00015	CcSEcCtD
Anagrelide—Pain—Topiramate—epilepsy syndrome	7.45e-05	0.00015	CcSEcCtD
Anagrelide—Asthenia—Gabapentin—epilepsy syndrome	7.43e-05	0.000149	CcSEcCtD
Anagrelide—Nausea—Valproic Acid—epilepsy syndrome	7.42e-05	0.000149	CcSEcCtD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—POMC—epilepsy syndrome	7.38e-05	0.00127	CbGpPWpGaD
Anagrelide—Pruritus—Gabapentin—epilepsy syndrome	7.33e-05	0.000147	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—CHRM2—epilepsy syndrome	7.32e-05	0.00126	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—BDKRB1—epilepsy syndrome	7.32e-05	0.00126	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CX3CL1—epilepsy syndrome	7.32e-05	0.00126	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—ALB—epilepsy syndrome	7.31e-05	0.00126	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—SRC—epilepsy syndrome	7.27e-05	0.00125	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—epilepsy syndrome	7.27e-05	0.00125	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—NEU1—epilepsy syndrome	7.2e-05	0.00124	CbGpPWpGaD
Anagrelide—Vomiting—Pregabalin—epilepsy syndrome	7.18e-05	0.000144	CcSEcCtD
Anagrelide—Feeling abnormal—Topiramate—epilepsy syndrome	7.18e-05	0.000144	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—CDC42—epilepsy syndrome	7.15e-05	0.00123	CbGpPWpGaD
Anagrelide—Gastrointestinal pain—Topiramate—epilepsy syndrome	7.13e-05	0.000143	CcSEcCtD
Anagrelide—Rash—Pregabalin—epilepsy syndrome	7.12e-05	0.000143	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—GABBR1—epilepsy syndrome	7.12e-05	0.00123	CbGpPWpGaD
Anagrelide—Dermatitis—Pregabalin—epilepsy syndrome	7.12e-05	0.000143	CcSEcCtD
Anagrelide—Diarrhoea—Gabapentin—epilepsy syndrome	7.09e-05	0.000142	CcSEcCtD
Anagrelide—Headache—Pregabalin—epilepsy syndrome	7.08e-05	0.000142	CcSEcCtD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—epilepsy syndrome	7.08e-05	0.00122	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—HSD17B4—epilepsy syndrome	6.93e-05	0.0012	CbGpPWpGaD
Anagrelide—Urticaria—Topiramate—epilepsy syndrome	6.93e-05	0.000139	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—AVP—epilepsy syndrome	6.92e-05	0.00119	CbGpPWpGaD
Anagrelide—Abdominal pain—Topiramate—epilepsy syndrome	6.89e-05	0.000138	CcSEcCtD
Anagrelide—Body temperature increased—Topiramate—epilepsy syndrome	6.89e-05	0.000138	CcSEcCtD
Anagrelide—Dizziness—Gabapentin—epilepsy syndrome	6.85e-05	0.000138	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—HRH3—epilepsy syndrome	6.83e-05	0.00118	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—OPRM1—epilepsy syndrome	6.72e-05	0.00116	CbGpPWpGaD
Anagrelide—Nausea—Pregabalin—epilepsy syndrome	6.71e-05	0.000135	CcSEcCtD
Anagrelide—Vomiting—Gabapentin—epilepsy syndrome	6.59e-05	0.000132	CcSEcCtD
Anagrelide—Rash—Gabapentin—epilepsy syndrome	6.53e-05	0.000131	CcSEcCtD
Anagrelide—Dermatitis—Gabapentin—epilepsy syndrome	6.53e-05	0.000131	CcSEcCtD
Anagrelide—Headache—Gabapentin—epilepsy syndrome	6.49e-05	0.00013	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—CCR5—epilepsy syndrome	6.48e-05	0.00112	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCR3—epilepsy syndrome	6.35e-05	0.00109	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—HTR2A—epilepsy syndrome	6.35e-05	0.00109	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ASAH1—epilepsy syndrome	6.29e-05	0.00109	CbGpPWpGaD
Anagrelide—Asthenia—Topiramate—epilepsy syndrome	6.25e-05	0.000126	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—NPY—epilepsy syndrome	6.19e-05	0.00107	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ATP2A2—epilepsy syndrome	6.19e-05	0.00107	CbGpPWpGaD
Anagrelide—Pruritus—Topiramate—epilepsy syndrome	6.17e-05	0.000124	CcSEcCtD
Anagrelide—Nausea—Gabapentin—epilepsy syndrome	6.15e-05	0.000124	CcSEcCtD
Anagrelide—CYP1A2—Metabolism—CA13—epilepsy syndrome	6.1e-05	0.00105	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—epilepsy syndrome	6.06e-05	0.00105	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—epilepsy syndrome	6.06e-05	0.00105	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—AGT—epilepsy syndrome	6.02e-05	0.00104	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HSPB1—epilepsy syndrome	5.97e-05	0.00103	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CRH—epilepsy syndrome	5.97e-05	0.00103	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—OXT—epilepsy syndrome	5.97e-05	0.00103	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CXCL2—epilepsy syndrome	5.97e-05	0.00103	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCL3—epilepsy syndrome	5.97e-05	0.00103	CbGpPWpGaD
Anagrelide—Diarrhoea—Topiramate—epilepsy syndrome	5.96e-05	0.00012	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—CCR5—epilepsy syndrome	5.89e-05	0.00102	CbGpPWpGaD
Anagrelide—Dizziness—Topiramate—epilepsy syndrome	5.76e-05	0.000116	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—HTR2A—epilepsy syndrome	5.76e-05	0.000994	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PRKCB—epilepsy syndrome	5.56e-05	0.00096	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TSC1—epilepsy syndrome	5.55e-05	0.000957	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PTK2B—epilepsy syndrome	5.55e-05	0.000957	CbGpPWpGaD
Anagrelide—Vomiting—Topiramate—epilepsy syndrome	5.54e-05	0.000111	CcSEcCtD
Anagrelide—Rash—Topiramate—epilepsy syndrome	5.5e-05	0.00011	CcSEcCtD
Anagrelide—Dermatitis—Topiramate—epilepsy syndrome	5.49e-05	0.00011	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—AGT—epilepsy syndrome	5.47e-05	0.000943	CbGpPWpGaD
Anagrelide—Headache—Topiramate—epilepsy syndrome	5.46e-05	0.00011	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—CCR2—epilepsy syndrome	5.4e-05	0.000931	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SST—epilepsy syndrome	5.4e-05	0.000931	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NTRK2—epilepsy syndrome	5.4e-05	0.000931	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—DUSP6—epilepsy syndrome	5.35e-05	0.000923	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ADRA2A—epilepsy syndrome	5.28e-05	0.000911	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PLAT—epilepsy syndrome	5.26e-05	0.000907	CbGpPWpGaD
Anagrelide—Nausea—Topiramate—epilepsy syndrome	5.18e-05	0.000104	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—SRC—epilepsy syndrome	5.17e-05	0.000892	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CXCL12—epilepsy syndrome	5.08e-05	0.000875	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—BDKRB2—epilepsy syndrome	5.08e-05	0.000875	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—POMC—epilepsy syndrome	5.07e-05	0.000874	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PRKCB—epilepsy syndrome	5.05e-05	0.000871	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—VEGFA—epilepsy syndrome	5.04e-05	0.000869	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—IL6ST—epilepsy syndrome	5.03e-05	0.000868	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—JUNB—epilepsy syndrome	4.98e-05	0.000859	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CNR1—epilepsy syndrome	4.98e-05	0.000859	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PLCB1—epilepsy syndrome	4.96e-05	0.000856	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—TXNRD1—epilepsy syndrome	4.91e-05	0.000847	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HTR7—epilepsy syndrome	4.86e-05	0.000838	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HBEGF—epilepsy syndrome	4.72e-05	0.000814	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AKT3—epilepsy syndrome	4.63e-05	0.000799	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CERS1—epilepsy syndrome	4.63e-05	0.000798	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ADK—epilepsy syndrome	4.63e-05	0.000798	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—FAR1—epilepsy syndrome	4.63e-05	0.000798	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PDXK—epilepsy syndrome	4.63e-05	0.000798	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GLUD1—epilepsy syndrome	4.63e-05	0.000798	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—L2HGDH—epilepsy syndrome	4.63e-05	0.000798	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—POMC—epilepsy syndrome	4.6e-05	0.000794	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ADAM10—epilepsy syndrome	4.52e-05	0.00078	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CCL2—epilepsy syndrome	4.5e-05	0.000777	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—S100B—epilepsy syndrome	4.28e-05	0.000738	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SOCS3—epilepsy syndrome	4.24e-05	0.000731	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NHLRC1—epilepsy syndrome	4.23e-05	0.00073	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PNPO—epilepsy syndrome	4.23e-05	0.00073	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—EPM2A—epilepsy syndrome	4.23e-05	0.00073	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GAMT—epilepsy syndrome	4.23e-05	0.00073	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CDC42—epilepsy syndrome	4.23e-05	0.000729	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AVP—epilepsy syndrome	4.09e-05	0.000706	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—QDPR—epilepsy syndrome	3.93e-05	0.000678	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CA4—epilepsy syndrome	3.93e-05	0.000678	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—POMC—epilepsy syndrome	3.92e-05	0.000676	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HES1—epilepsy syndrome	3.87e-05	0.000667	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FYN—epilepsy syndrome	3.76e-05	0.000649	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—H2AFX—epilepsy syndrome	3.75e-05	0.000646	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MEF2C—epilepsy syndrome	3.74e-05	0.000645	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—COX3—epilepsy syndrome	3.7e-05	0.000638	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—YWHAZ—epilepsy syndrome	3.62e-05	0.000624	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NGF—epilepsy syndrome	3.58e-05	0.000617	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—KCNB1—epilepsy syndrome	3.51e-05	0.000605	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CACNA2D2—epilepsy syndrome	3.51e-05	0.000605	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SLCO1A2—epilepsy syndrome	3.51e-05	0.000605	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PFKL—epilepsy syndrome	3.51e-05	0.000605	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SLC6A8—epilepsy syndrome	3.51e-05	0.000605	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCR5—epilepsy syndrome	3.48e-05	0.0006	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CYP2C19—epilepsy syndrome	3.43e-05	0.000591	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CYP11A1—epilepsy syndrome	3.41e-05	0.000587	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HTR2A—epilepsy syndrome	3.4e-05	0.000587	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TSC2—epilepsy syndrome	3.23e-05	0.000558	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AGT—epilepsy syndrome	3.23e-05	0.000557	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—AKT1—epilepsy syndrome	3.21e-05	0.000554	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NEU1—epilepsy syndrome	3.21e-05	0.000553	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—UPB1—epilepsy syndrome	3.21e-05	0.000553	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ATIC—epilepsy syndrome	3.21e-05	0.000553	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—APOE—epilepsy syndrome	3.16e-05	0.000546	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—KDR—epilepsy syndrome	3.1e-05	0.000535	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HSD17B4—epilepsy syndrome	3.09e-05	0.000532	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PRKCB—epilepsy syndrome	2.98e-05	0.000515	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GBE1—epilepsy syndrome	2.98e-05	0.000514	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PPP1R3C—epilepsy syndrome	2.98e-05	0.000514	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IL6ST—epilepsy syndrome	2.97e-05	0.000513	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—epilepsy syndrome	2.91e-05	0.000503	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ASAH1—epilepsy syndrome	2.8e-05	0.000483	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—STXBP1—epilepsy syndrome	2.73e-05	0.00047	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—POMC—epilepsy syndrome	2.72e-05	0.000469	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCL2—epilepsy syndrome	2.66e-05	0.000459	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NT5E—epilepsy syndrome	2.66e-05	0.000458	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALAD—epilepsy syndrome	2.66e-05	0.000458	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CACNA1A—epilepsy syndrome	2.53e-05	0.000437	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALDH7A1—epilepsy syndrome	2.53e-05	0.000437	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ST3GAL3—epilepsy syndrome	2.48e-05	0.000428	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ADSL—epilepsy syndrome	2.43e-05	0.000419	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FGF2—epilepsy syndrome	2.4e-05	0.000415	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GLUL—epilepsy syndrome	2.38e-05	0.000411	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CACNA1D—epilepsy syndrome	2.34e-05	0.000403	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—RELA—epilepsy syndrome	2.23e-05	0.000385	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MTOR—epilepsy syndrome	2.19e-05	0.000377	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—TXNRD1—epilepsy syndrome	2.19e-05	0.000377	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—AQP1—epilepsy syndrome	2.12e-05	0.000366	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—epilepsy syndrome	2.04e-05	0.000352	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—AKT1—epilepsy syndrome	2.03e-05	0.00035	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CASP3—epilepsy syndrome	2.01e-05	0.000347	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—JUN—epilepsy syndrome	1.96e-05	0.000337	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CHRM3—epilepsy syndrome	1.92e-05	0.000331	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—KCNJ11—epilepsy syndrome	1.92e-05	0.000331	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MMP9—epilepsy syndrome	1.9e-05	0.000328	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—AKT1—epilepsy syndrome	1.84e-05	0.000318	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	1.79e-05	0.000309	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SRC—epilepsy syndrome	1.75e-05	0.000302	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	1.75e-05	0.000302	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—VEGFA—epilepsy syndrome	1.71e-05	0.000295	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ABCG2—epilepsy syndrome	1.57e-05	0.00027	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP2C19—epilepsy syndrome	1.53e-05	0.000263	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP11A1—epilepsy syndrome	1.52e-05	0.000262	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	1.51e-05	0.00026	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	1.37e-05	0.000237	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP2D6—epilepsy syndrome	1.37e-05	0.000236	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ADRA2A—epilepsy syndrome	1.3e-05	0.000225	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—BCHE—epilepsy syndrome	1.3e-05	0.000224	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SLC2A1—epilepsy syndrome	1.24e-05	0.000214	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PLCB1—epilepsy syndrome	1.22e-05	0.000211	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—TH—epilepsy syndrome	1.22e-05	0.00021	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	1.2e-05	0.000207	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AKT1—epilepsy syndrome	1.09e-05	0.000188	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HMOX1—epilepsy syndrome	1.02e-05	0.000176	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CAT—epilepsy syndrome	1e-05	0.000173	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ABCB1—epilepsy syndrome	9.77e-06	0.000169	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GPX1—epilepsy syndrome	9.09e-06	0.000157	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—AGT—epilepsy syndrome	7.97e-06	0.000137	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—APOE—epilepsy syndrome	7.81e-06	0.000135	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—POMC—epilepsy syndrome	6.71e-06	0.000116	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALB—epilepsy syndrome	6.11e-06	0.000105	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PTGS2—epilepsy syndrome	5.35e-06	9.23e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—AKT1—epilepsy syndrome	2.69e-06	4.64e-05	CbGpPWpGaD
